Can Zepbound or Ozempic Treat Sleep Apnea? What the FDA Approval Actually Means
💙 First, take a breath. The FDA approved Zepbound (tirzepatide) for moderate-to-severe sleep apnea in adults with obesity in December 2024 — the first drug ever cleared for this use. That's real, hopeful news. But it doesn't replace a sleep study, and it doesn't replace CPAP for most people. Here's what the approval actually changed, and what it didn't.
If you have sleep apnea and you also struggle with your weight, you've probably asked the question everyone is asking: can one of these shots fix the apnea too?
The honest answer: in some people, it cuts apnea a lot. In a smaller group, it cuts it enough that they may no longer need a breathing machine. But the FDA approval is narrower than the headlines suggest, and a lot of patients are asking for the wrong drug.
This is a plain walk-through. What got approved, what didn't, who qualifies, what the trial showed, what the side effects are, and how to take the next step.
What got approved (and what didn't)
In December 2024, the FDA approved Zepbound — the brand name for tirzepatide, made by Eli Lilly — for adults with moderate-to-severe obstructive sleep apnea (OSA) and obesity. It is the first prescription drug ever approved specifically for sleep apnea.
The headlines blurred a few facts. Here they are straight:
Zepbound is not Ozempic. Tirzepatide (Zepbound, Mounjaro) and semaglutide (Ozempic, Wegovy) are different molecules. Only Zepbound has the OSA approval.
Ozempic is not approved for sleep apnea. Ozempic is approved for type 2 diabetes. Wegovy is approved for weight management. Neither is approved for OSA.
Mounjaro is not approved for sleep apnea either, even though it is the same drug as Zepbound. Mounjaro is the diabetes label; Zepbound is the obesity label. The OSA approval sits with Zepbound.
The approval covers moderate-to-severe OSA only, not mild apnea. That means an AHI of 15 or higher. (AHI, the apnea-hypopnea index, is the number of breathing pauses per hour during sleep. Under 5 is normal, 5–15 is mild, 15–30 is moderate, over 30 is severe.)
The approval requires obesity — typically a BMI of 30 or higher. People without obesity were not in the studies.
If you are thin and have sleep apnea, this approval does not apply to you. If you have mild apnea, it does not apply to you. If your insurance is asked to cover Mounjaro or Ozempic for apnea, it will deny it. Those labels do not include OSA.
Most people skip the first real question: how severe is your apnea, and what is driving it? You answer that with a current sleep study and a doctor who reads it with you — not with a headline.
Know your risk. Most people have never had their apnea risk scored. Take the STOP-BANG questionnaire and find out where you stand in a few minutes. Check your sleep apnea risk.
What the SURMOUNT-OSA trial actually showed
The approval was built on two trials called SURMOUNT-OSA, published in the New England Journal of Medicine in 2024 (Malhotra et al.).
The setup: about 470 adults with obesity and moderate-to-severe OSA. Half were on CPAP at the start, half were not. Everyone was randomized to either tirzepatide (up to 15 mg weekly) or a placebo injection, for 52 weeks.
The result: at one year, people on tirzepatide cut their AHI by roughly 25 to 30 events per hour more than placebo. That is about a 50–60% reduction in breathing pauses. Many participants also lost 18–20% of their body weight.
A meaningful share dropped from moderate-to-severe into mild or normal AHI. About 40–50% of tirzepatide patients hit the trial's "disease resolution" threshold — an AHI under 5, or an AHI of 5–15 without significant daytime sleepiness.
Here is what those numbers do not mean:
They do not mean every patient was cured.
They do not mean tirzepatide beat CPAP. The trial was not a head-to-head comparison.
They do not mean patients can stop CPAP without re-testing. The follow-up sleep studies that confirmed the AHI changes were done inside the trial. A real-world doctor would do the same before telling you to stop your machine.
What the data does show: for adults with obesity and significant sleep apnea, tirzepatide produced the largest medication-driven AHI reductions ever seen in a major OSA trial. That is why the approval happened.
Why weight loss helps the airway
Sleep apnea does not have one single cause. But for a large share of patients, excess weight around the neck and tongue is the main driver. Fat in the soft tissue of the throat and the base of the tongue narrows the airway. When you fall asleep and the throat muscles relax, that narrow airway is more likely to collapse — hundreds of times a night.
Lose weight, and that tissue thins. The airway is less crowded. It collapses less. The number of pauses per hour drops. This has been known for decades. Researchers have even worked out how many pounds it takes to drop an apnea severity category.
What is new is not the principle. What is new is a medication that produces enough sustained weight loss, in enough people, to move the AHI in a way that matters. If you are weighing the drugs themselves, we cover how GLP-1 medications work for apnea.
Who is (and isn't) a good candidate
A useful conversation with a doctor starts with these factors.
You may be a reasonable candidate if:
You have been diagnosed by a sleep study with moderate-to-severe OSA (AHI 15 or higher)
Your BMI is 30 or higher
You are trying CPAP but tolerating it poorly, or you want to treat the underlying driver
You do not have a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 (both are absolute contraindications for GLP-1-class drugs)
You do not have a history of pancreatitis or severe gastroparesis
You are not pregnant, breastfeeding, or planning pregnancy soon
You are probably not a good candidate if:
You have mild OSA (AHI under 15). The approval does not cover you.
Your BMI is under 30. The approval does not cover you, and the trial did not study you.
Your apnea is mainly positional, anatomical (large tonsils, severely deviated septum), or central (driven by brain signaling, not airway collapse)
You have unstable cardiac disease, severe GI motility problems, or an active eating disorder.
A large share of patients with sleep apnea do not fit the obesity-driven profile at all. Thin patients with crowded airways, patients with craniofacial anatomy issues, and patients with central sleep apnea were not the people this drug was studied in. For them, CPAP, oral appliances, positional therapy, and surgery remain the right conversations. The right next step depends entirely on which kind of apnea you have — and that is a question for a doctor who knows your history, not a prescription pad that only knows your weight.
Find your doctor.
Get matched with a doctor licensed in your state who will read your results, weigh your BMI and your other conditions together, and tell you which treatment path is actually yours.
Find a sleep doctor
Side effects, including the parts no one wants to discuss
The side effects of Zepbound, like other GLP-1-class drugs, are real. Know them before you start.
Common, and often manageable:
Nausea, especially in the first few weeks and after dose increases
Diarrhea or constipation
Reflux, burping, and feeling full all the time
Fatigue
Injection-site irritation
Less common but more serious:
Pancreatitis. Sudden, severe upper abdominal pain that goes through to the back is a red flag. Stop the drug and get evaluated.
Gallbladder disease, especially during rapid weight loss
Severe gastroparesis (delayed stomach emptying), which can complicate any future surgery needing anesthesia. Tell your surgeon and anesthesiologist if you are on a GLP-1.
Dehydration and kidney injury, usually downstream of nausea and vomiting
A boxed warning about thyroid C-cell tumors, based on rodent studies. The human risk is unclear, but a personal or family history of medullary thyroid cancer is an absolute no.
There is also a practical fact: if you stop the drug, much of the weight tends to come back, and the AHI tends to rise with it. This is open-ended treatment, not a 12-week course. That is a budget conversation as much as a clinical one — and whether Medicare and private insurers will pay for it is still a patchwork.
How this fits with CPAP
This is the question I get asked most, so here it is directly: for now, the gold-standard treatment for moderate-to-severe obstructive sleep apnea is still CPAP. That has not changed. CPAP works the night you put it on. Weight-loss medication takes months to move the AHI.
What is reasonable in practice today:
Newly diagnosed with moderate-to-severe OSA and obesity? Start CPAP now. It treats the apnea immediately, lowers cardiovascular and accident risk, and gives you a measurable baseline. Discuss tirzepatide with your doctor as a parallel track that may, over a year or two, reduce your apnea enough to revisit therapy.
Already on CPAP and doing well? Do not stop your machine to start tirzepatide. The two work together; they are not interchangeable.
On tirzepatide and lost meaningful weight? The next step is a repeat sleep study, not a self-experiment. If the new AHI is low enough, your doctor can talk you through whether to continue, reduce, or pause CPAP.
Intolerant of CPAP for years? Tirzepatide plus an oral appliance, or tirzepatide plus positional therapy, may be a more workable long-term plan than CPAP alone. That is an individual conversation with a clinician.
The mistake we keep seeing: patients quietly stop their CPAP the week they start the injection, because they have decided the drug is the new treatment. It is not. Not yet, and probably not for most people.
Should I worry?
Sleep apnea is not a minor inconvenience. Left untreated, it raises the risk of high blood pressure, heart disease, and stroke — the full list of conditions it drives is longer than most people expect.
Some symptoms warrant a call to your doctor this week, wherever you are in this process:
Falling asleep at the wheel or while operating machinery
Witnessed choking, gasping, or stopped breathing during sleep
Severe daytime sleepiness affecting work, driving, or parenting
Chest pain, palpitations, or new shortness of breath
Severe abdominal pain, especially with vomiting, on a GLP-1 — a possible pancreatitis sign
Any sudden, severe headache or neurological change
For non-urgent concerns — CPAP feeling less effective, a weight-loss plateau, or wondering whether you still need a machine after losing weight — bring it up at your next visit. Do not change your therapy on your own.
What to do next
Confirm your diagnosis with a current sleep study. If your last one was years ago, your AHI today may be different, in either direction.
Bring the question to a doctor who treats sleep, not just a quick-visit prescriber. Some offices hand out tirzepatide for weight loss without the apnea conversation. You want both pieces handled by someone who knows your history.
Do not pause CPAP unless your doctor explicitly says it is reasonable, ideally after a repeat sleep study.
Plan for the long haul. GLP-1 therapy is open-ended. Cost, coverage, and side-effect tolerance matter as much as the headline efficacy.
This approval is a real expansion of what is possible in sleep medicine. It is not a magic bullet, and it is not for everyone. For the right patient, treated alongside gold-standard care, it is one of the most promising tools in years.
Your next step
The most useful thing you can do this week is get in front of a doctor who treats the whole picture — your sleep, your weight, and your other conditions together — instead of one number on a lab report.
Find your doctor. Get matched with a doctor licensed in your state who can order at-home testing and build a plan that fits you. Find a sleep doctor
Not sure you need one yet? Take the STOP-BANG questionnaire first and see where you stand. Check your sleep apnea risk.